Adaptimmune Therapeutics PLC Quarterly Operating Income (Loss) in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Operating Income (Loss) history and growth rate from Q1 2015 to Q2 2024.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the quarter ending June 30, 2024 was $68.7M.
  • Adaptimmune Therapeutics PLC Operating Income (Loss) for the twelve months ending June 30, 2024 was -$77.1M, a 32.1% increase year-over-year.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2023 was -$140M, a 14.8% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2022 was -$164M, a 1.06% decline from 2021.
  • Adaptimmune Therapeutics PLC annual Operating Income (Loss) for 2021 was -$162M, a 21.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$77.1M $68.7M +$114M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$191M -$49.3M -$50.9M -3075% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$140M -$49.9M -$22.6M -83% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$117M -$46.6M -$3.64M -8.47% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$113M -$44.9M -$1.16M -2.64% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$112M $1.66M +$51.6M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$164M -$27.2M +$15.6M +36.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$180M -$43M -$809K -1.92% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$179M -$43.8M -$4.44M -11.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$174M -$50M -$12.1M -31.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$162M -$42.9M -$5.35M -14.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$157M -$42.2M -$6.31M -17.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$151M -$39.3M -$9.06M -29.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$142M -$37.9M -$8.13M -27.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$133M -$37.5M -$7.16M -23.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 -$126M -$35.9M +$4.25M +10.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$130M -$30.3M +$5.25M +14.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$136M -$29.8M +$4.03M +11.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$140M -$30.4M +$1.41M +4.44% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 -$141M -$40.1M -$47.1M -672% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$94M -$35.5M -$6.63M -22.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$87.4M -$33.8M -$5.05M -17.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$82.4M -$31.8M -$2.07M -6.96% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$80.3M $7.02M +$12M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 -$92.3M -$28.9M -$5.1M -21.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$87.2M -$28.7M -$6.52M -29.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 -$80.7M -$29.7M -$15M -103% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$65.6M -$4.96M +$13.7M +73.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$79.3M -$23.8M -$1.08M -4.76% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 -$78.2M -$22.2M -$5.4M -32.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$72.8M -$14.7M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 -$18.6M -$10.3M -124% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 -$22.7M -$11.6M -104% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 -$16.8M -$11.2M -200% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 -$8.31M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$11.1M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 -$5.61M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.